[6] Phase III ACHIEVE-1 trial [edit] In April 2025, results from a phase III clinical trial involving 559 people with type 2 diabetes who took an oral orforglipron pill or a placebo daily for 40 weeks showed that orforglipron produced a reduction of hemoglobin A1C level by 1.3 to 1.6 percentage points from a starting level of 8%
Metabo Brain Dis 32(5):17351745 Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH (2000) An association between migraine and cutaneous allodynia
Section S0 applies broadly to pharmacological substances that are not addressed elsewhere and have no current approval by a governmental regulatory health authority for human therapeutic use
For a broader overview of how peptides are used in veterinary contexts including BPC-157, TB-500, and GHK-Cu, see our guide to peptides for dogs
doi: 10.1016/J.CELL.2024.08.021 14
Therapeutic approach of kras mutant tumours by the combination of pharmacologic ascorbate and chloroquine
